Literature DB >> 23971860

Development of hairy cell leukemia in familial platelet disorder with predisposition to acute myeloid leukemia.

Takashi Toya1, Akihide Yoshimi, Takehiko Morioka, Shunya Arai, Motoshi Ichikawa, Kensuke Usuki, Mineo Kurokawa.   

Abstract

Abstract Familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML) is an autosomal dominant disorder characterized by mild to moderate thrombocytopenia with or without its impaired function, inherited RUNX1 mutation and high incidence of myeloid malignancy, such as myelodysplastic syndrome or acute myeloid leukemia. A 72-year-old male visited our institute because of gradually progressive pancytopenia and splenomegaly, and was diagnosed as having hairy cell leukemia. He was administered one course of intravenous cladribine (0.12 mg/kg, day 1-5) and achieved hematological complete response. Mutation analyses of RUNX1 gene were underwent because familial history of hematological malignancies evoked a possibility of FPD/AML. As a result, RUNX1 L445P mutation was identified in the peripheral blood and the mutation was considered as germ-line mutation because the same mutation was detected in the buccal mucosa. BRAF V600E mutation was also identified in the peripheral blood but not in the buccal mucosa. To our knowledge, this is the first report of B cell malignancy arising from FPD/AML.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23971860     DOI: 10.3109/09537104.2013.818636

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  7 in total

Review 1.  Role of RUNX1 in hematological malignancies.

Authors:  Raman Sood; Yasuhiko Kamikubo; Paul Liu
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

Review 2.  Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).

Authors:  Anna L Brown; Christopher N Hahn; Hamish S Scott
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

Review 3.  Familial leukemias.

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2015-02

4.  ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants.

Authors:  Xi Luo; Simone Feurstein; Shruthi Mohan; Christopher C Porter; Sarah A Jackson; Sioban Keel; Michael Chicka; Anna L Brown; Chimene Kesserwan; Anupriya Agarwal; Minjie Luo; Zejuan Li; Justyne E Ross; Panagiotis Baliakas; Daniel Pineda-Alvarez; Courtney D DiNardo; Alison A Bertuch; Nikita Mehta; Tom Vulliamy; Ying Wang; Kim E Nichols; Luca Malcovati; Michael F Walsh; Lesley H Rawlings; Shannon K McWeeney; Jean Soulier; Anna Raimbault; Mark J Routbort; Liying Zhang; Gabriella Ryan; Nancy A Speck; Sharon E Plon; David Wu; Lucy A Godley
Journal:  Blood Adv       Date:  2019-10-22

5.  Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation.

Authors:  Rashmi Kanagal-Shamanna; Sanam Loghavi; Courtney D DiNardo; L Jeffrey Medeiros; Guillermo Garcia-Manero; Elias Jabbour; Mark J Routbort; Rajyalakshmi Luthra; Carlos E Bueso-Ramos; Joseph D Khoury
Journal:  Haematologica       Date:  2017-06-28       Impact factor: 9.941

Review 6.  How I curate: applying American Society of Hematology-Clinical Genome Resource Myeloid Malignancy Variant Curation Expert Panel rules for RUNX1 variant curation for germline predisposition to myeloid malignancies.

Authors:  David Wu; Xi Luo; Simone Feurstein; Chimene Kesserwan; Shruthi Mohan; Daniel E Pineda-Alvarez; Lucy A Godley
Journal:  Haematologica       Date:  2020-03-12       Impact factor: 9.941

Review 7.  Adult-onset hereditary myeloid malignancy and allogeneic stem cell transplantation.

Authors:  Takashi Toya; Hironori Harada; Yuka Harada; Noriko Doki
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.